Among the investigated antibodies, lenzilumab (a recombinant monoclonal antibody against GM-CSF)333 and mavrilimumab (a monoclonal antibody against GM-CSFRα)334 have been shown in small prospective cohort studies to be associated with reduced mortality and improved systemic hyperinflammation in patients with severe COVID-19. The gene discussed is CSF2; the disease is COVID-19.